A new topical treatment for male-pattern baldness has shown remarkable results in late-stage clinical trials, offering hope after decades of limited options. The drug, clascoterone 5% solution, demonstrated significant hair regrowth with a safety profile comparable to placebo.
Dublin-based Cosmo Pharmaceuticals reported topline results from two large phase 3 trials, SCALP-1 and SCALP-2, which together enrolled 1,465 men across the United States and Europe—the largest phase 3 program for a topical hair-loss treatment to date.
One trial showed a 539% relative increase in hair count compared with placebo, while the other showed a 168% improvement. Both results were statistically significant.
Unlike traditional hair-loss treatments, which either act weakly on the scalp or block hormones systemically, clascoterone targets dihydrotestosterone (DHT) directly at the hair follicle. DHT is a primary driver of male-pattern baldness, and systemic DHT blockers can cause side effects such as sexual dysfunction. By acting locally, clascoterone avoids significant absorption into the bloodstream. This represents the first new molecular mechanism for hair-loss therapy in more than 30 years.
Safety data were encouraging. Treatment-related side effects were rare, mild, and similar to placebo. No meaningful hormonal disturbances were observed. Patient-reported outcomes, including perceived hair coverage and satisfaction, aligned with measured hair-count improvements, indicating visible and tangible results for participants.
Dermatologists have described the findings as potentially transformative. Dr. Maria Hordinsky of the University of Minnesota said: “For decades, patients have faced limited efficacy or safety concerns with existing options. Clascoterone 5% topical solution delivers real, measurable regrowth with negligible systemic exposure, potentially redefining treatment for androgenetic alopecia worldwide.”
Cosmo CEO Giovanni Di Napoli emphasized the emotional impact of male-pattern baldness, noting that this treatment could change the therapeutic model for the first time in three decades.
However, full peer-reviewed data are still pending, and long-term maintenance of hair growth remains a key consideration. Cosmo plans to complete a 12-month safety follow-up by spring 2026, followed by regulatory submissions to the U.S. Food and Drug Administration and the European Medicines Agency. If approved, the treatment could be available in pharmacies by 2027.
Related topic：
